View ValuationLärkberget 将来の成長Future 基準チェック /06現在、 Lärkbergetの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長7.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Marcus Isaksson is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Feb 13+ 1 more updateLärkberget AB (publ) announces Annual dividend, payable on May 15, 2026Lärkberget AB (publ) announced Annual dividend of SEK 2.0000 per share payable on May 15, 2026, ex-date on May 08, 2026 and record date on May 11, 2026.お知らせ • May 24CombiGene AB (publ) announces Annual dividend, payable on June 19, 2025CombiGene AB (publ) announced Annual dividend of SEK 0.2000 per share payable on June 19, 2025, ex-date on June 13, 2025 and record date on June 16, 2025.お知らせ • May 15CombiGene AB (publ), Annual General Meeting, Jun 12, 2025CombiGene AB (publ), Annual General Meeting, Jun 12, 2025, at 11:30 W. Europe Standard Time. Location: at combigene c/o aboutvalue, nybrogatan 7, stockholm Swedenお知らせ • Jan 10+ 1 more updateStockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.お知らせ • Dec 17+ 1 more updateCombiGene AB (publ) to Report First Half, 2025 Results on Aug 22, 2025CombiGene AB (publ) announced that they will report first half, 2025 results on Aug 22, 2025Reported Earnings • Nov 10Third quarter 2024 earnings released: kr0.45 loss per share (vs kr0.42 loss in 3Q 2023)Third quarter 2024 results: kr0.45 loss per share (further deteriorated from kr0.42 loss in 3Q 2023). Net loss: kr8.96m (loss widened 6.6% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.38 loss per share (vs kr0.32 loss in 2Q 2023)Second quarter 2024 results: kr0.38 loss per share (further deteriorated from kr0.32 loss in 2Q 2023). Net loss: kr7.57m (loss widened 20% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.New Risk • Aug 25New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Revenue is less than US$1m (kr4.3m revenue, or US$422k). Market cap is less than US$10m (€5.04m market cap, or US$5.64m).お知らせ • May 29Combigene AB (Publ) Appoints Annika Ericsson as New Chief Scientific OfficerCombiGene AB (publ) announced that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin Agerman, who has decided to leave the company. Annika has worked almost as long as Karin in the company and has solid experience in drug development of gene therapies in the preclinical phase and project management. She started by running the preclinical testing of CG01 and has subsequently been project manager in several projects, most recently for CGT2, the lipodystrophy project, and COZY02, CombiGene's latest gene therapy project that targets severe chronic pain where there is currently a lack of good treatment options.お知らせ • May 24CombiGene AB (publ) Approves Election of Marcus Isaksson as Board MemberCombiGene AB (publ) at its AGM held on May 23, 2024 approved election of Marcus Isaksson, as board member.Reported Earnings • May 19First quarter 2024 earnings released: kr0.72 loss per share (vs kr0.74 loss in 1Q 2023)First quarter 2024 results: kr0.72 loss per share (improved from kr0.74 loss in 1Q 2023). Net loss: kr14.2m (loss narrowed 2.9% from 1Q 2023).お知らせ • Mar 13CombiGene's Epilepsy Project CG01 Receives Patent in Two New CountriesCombiGene AB (publ) announced that the patent offices in Australia and India have granted patent for the epilepsy project CG01. The approval strengthens the project, which CombiGene recently has regained the global rights to.CG01 has previously been granted patents in the USA and Russia. CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.Reported Earnings • Feb 18Full year 2023 earnings released: kr1.80 loss per share (vs kr0.31 loss in FY 2022)Full year 2023 results: kr1.80 loss per share (further deteriorated from kr0.31 loss in FY 2022). Net loss: kr35.7m (loss widened 479% from FY 2022).お知らせ • Dec 15+ 2 more updatesCombiGene AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025CombiGene AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Nov 12Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)Third quarter 2023 results: kr0.42 loss per share (down from kr0.20 profit in 3Q 2022). Revenue: kr1.17m (down 91% from 3Q 2022). Net loss: kr8.40m (down 313% from profit in 3Q 2022).お知らせ • Oct 25+ 1 more updateCombiGene AB (publ), Annual General Meeting, May 23, 2024CombiGene AB (publ), Annual General Meeting, May 23, 2024.New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.25m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (kr4.5m revenue, or US$409k). Market cap is less than US$10m (€9.25m market cap, or US$9.77m).Board Change • Sep 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 27Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.23 profit in 2Q 2022)Second quarter 2023 results: kr0.32 loss per share (down from kr0.23 profit in 2Q 2022). Net loss: kr6.29m (down 239% from profit in 2Q 2022).お知らせ • Jul 01CombiGene AB (publ) Announces Chief Executive Officer ChangesCombiGene AB (publ) announced that CEO Jan Nilsson will leave his position as CEO of the Company on September 1, 2023, when the Company's current COO Peter Ekolind will take over as CEO in accordance with current succession plan. Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industry. Many years of experience from a variety of positions have given Peter solid knowledge in product development, sales, marketing, preclinical development and GMP manufacturing. Peter has held several senior positions such as Business Area Manager, COO and CEO. He has served in a variety of firms, ranging from large multi-international companies to small development companies, with roles in business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiations, and research collaborations with universities. Peter has been Chief Operating Officer at CombiGene since September 2022. Jan Nilsson will continue to assist CombiGene on a consultancy basis, including the Company's involvement in the newly formed CCRM Nordic AB, where Jan was recently elected Chairman of the Board.Reported Earnings • May 14First quarter 2023 earnings released: kr0.74 loss per share (vs kr0.14 loss in 1Q 2022)First quarter 2023 results: kr0.74 loss per share (further deteriorated from kr0.14 loss in 1Q 2022). Revenue: kr2.17m (down 85% from 1Q 2022). Net loss: kr14.6m (loss widened 445% from 1Q 2022).Reported Earnings • Feb 18Full year 2022 earnings released: kr0.31 loss per share (vs kr1.21 profit in FY 2021)Full year 2022 results: kr0.31 loss per share (down from kr1.21 profit in FY 2021). Revenue: kr41.7m (down 54% from FY 2021). Net loss: kr6.16m (down 129% from profit in FY 2021).お知らせ • Dec 03+ 3 more updatesCombiGene AB (publ), Annual General Meeting, May 25, 2023CombiGene AB (publ), Annual General Meeting, May 25, 2023.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.20 (up from kr0.62 loss in 3Q 2021). Revenue: kr13.5m (up kr13.1m from 3Q 2021). Net income: kr3.95m (up kr14.2m from 3Q 2021). Profit margin: 29% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.20 (up from kr0.62 loss in 3Q 2021). Revenue: kr13.5m (up kr13.1m from 3Q 2021). Net income: kr3.95m (up kr14.2m from 3Q 2021). Profit margin: 29% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue.お知らせ • Sep 29CombiGene Appoints Peter Ekolind as COOCombiGene announced that Peter Ekolind joins the Company September 27, 2022, when he assumes the position of Chief Operating Officer, initially as a part-time assignment. Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industries. Many years of work in a variety of positions have given Peter a good knowledge of product development, sales, marketing preclinical development and GMP manufacturing. Peter has held several senior positions as, among other things, business area manager, COO and CEO. He has, in everything from large multi-international companies to small development companies, worked with business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiation and research collaborations with universities and colleges.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: kr0.23 (vs kr1.18 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.23 (up from kr1.18 loss in 2Q 2021). Revenue: kr14.6m (up kr13.8m from 2Q 2021). Net income: kr4.52m (up kr19.9m from 2Q 2021). Profit margin: 31% (up from net loss in 2Q 2021). The move to profitability was primarily driven by higher revenue.Reported Earnings • May 13First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.95 loss in 1Q 2021)First quarter 2022 results: kr0.14 loss per share (up from kr0.95 loss in 1Q 2021). Revenue: kr14.5m (up 183% from 1Q 2021). Net loss: kr2.68m (loss narrowed 75% from 1Q 2021).Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 21CombiGene AB (publ), Annual General Meeting, May 19, 2022CombiGene AB (publ), Annual General Meeting, May 19, 2022, at 10:00 Central European Standard Time. Location: Freys Hotell, Bryggargatan 12 in Stockholm Stockholm Sweden Agenda: To consider Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group; to consider adoption of the profit and loss account and the balance sheet as well as of the consolidated profit and loss account and the consolidated balance sheet; to consider allocation of the company’s profit or loss according to the adopted balance sheet; to consider discharge from liability for the board members and the CEO; to consider Resolution on the number of board members, deputy board members, auditors and deputy auditors; to consider Resolution on the remuneration to the board of directors and auditors; to consider Resolution on instruction for the nomination committee; and to consider other matters.お知らせ • Jan 18Combigene AB (Publ) Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human StudyCombiGene AB announced that the GMP production of CG01 has been made available for the concluding preclinical studies planned to enable First In Human study. This is the first large scale GMP production of CG01, and both the production itself and the subsequent testing were performed according to original plans. The data from the analyses will form a central part of future regulatory applications to support proceeding to clinical studies. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Lärkberget は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:COJ0 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-12-13-13N/A9/30/20250-27-17-17N/A6/30/20250-35-22-22N/A3/31/20251-37-25-25N/A12/31/20242-45-30-30N/A9/30/20243-37-31-31N/A6/30/20244-37-33-32N/A3/31/20246-35-30-30N/A12/31/20237-36-32-31N/A9/30/2023-8-41-30-30N/A6/30/20234-29-22-22N/A3/31/202317-18-12-12N/A12/31/202229-6-17-17N/A9/30/2022127636060N/A6/30/2022114494444N/A3/31/2022100292222N/A12/31/202191212222N/A9/30/20218-47-60-60N/A6/30/202111-44-53-53N/A3/31/202112-33-43-43N/A12/31/202011-29-38-38N/A9/30/202012-27-22-22N/A6/30/202016-24-30-30N/A3/31/202017-23-29-29N/A12/31/201915-18-22-22N/A9/30/201913-12N/A-36N/A6/30/20198-14N/A-6N/A3/31/20195-14N/A-1N/A12/31/20184-13N/A0N/A9/30/20182-13N/A7N/A6/30/20181-10N/A-7N/A3/31/20181-11N/A-9N/A12/31/20173-9N/A-10N/A9/30/20173-8N/A-10N/A6/30/20173-8N/A-11N/A3/31/20173-7N/A-9N/A12/31/2016N/A-9N/A-9N/A9/30/2016N/A-8N/A-7N/A6/30/2016N/A-7N/A-7N/A3/31/2016N/A-7N/A-7N/A12/31/2015N/A-6N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COJ0の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: COJ0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: COJ0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: COJ0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: COJ0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COJ0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 09:34終値2026/07/17 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lärkberget AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Niklas ElmhammerCarlsquare AB
Board Change • May 20No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Marcus Isaksson is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Feb 13+ 1 more updateLärkberget AB (publ) announces Annual dividend, payable on May 15, 2026Lärkberget AB (publ) announced Annual dividend of SEK 2.0000 per share payable on May 15, 2026, ex-date on May 08, 2026 and record date on May 11, 2026.
お知らせ • May 24CombiGene AB (publ) announces Annual dividend, payable on June 19, 2025CombiGene AB (publ) announced Annual dividend of SEK 0.2000 per share payable on June 19, 2025, ex-date on June 13, 2025 and record date on June 16, 2025.
お知らせ • May 15CombiGene AB (publ), Annual General Meeting, Jun 12, 2025CombiGene AB (publ), Annual General Meeting, Jun 12, 2025, at 11:30 W. Europe Standard Time. Location: at combigene c/o aboutvalue, nybrogatan 7, stockholm Sweden
お知らせ • Jan 10+ 1 more updateStockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
お知らせ • Dec 17+ 1 more updateCombiGene AB (publ) to Report First Half, 2025 Results on Aug 22, 2025CombiGene AB (publ) announced that they will report first half, 2025 results on Aug 22, 2025
Reported Earnings • Nov 10Third quarter 2024 earnings released: kr0.45 loss per share (vs kr0.42 loss in 3Q 2023)Third quarter 2024 results: kr0.45 loss per share (further deteriorated from kr0.42 loss in 3Q 2023). Net loss: kr8.96m (loss widened 6.6% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.38 loss per share (vs kr0.32 loss in 2Q 2023)Second quarter 2024 results: kr0.38 loss per share (further deteriorated from kr0.32 loss in 2Q 2023). Net loss: kr7.57m (loss widened 20% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 25New major risk - Revenue and earnings growthEarnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Revenue is less than US$1m (kr4.3m revenue, or US$422k). Market cap is less than US$10m (€5.04m market cap, or US$5.64m).
お知らせ • May 29Combigene AB (Publ) Appoints Annika Ericsson as New Chief Scientific OfficerCombiGene AB (publ) announced that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin Agerman, who has decided to leave the company. Annika has worked almost as long as Karin in the company and has solid experience in drug development of gene therapies in the preclinical phase and project management. She started by running the preclinical testing of CG01 and has subsequently been project manager in several projects, most recently for CGT2, the lipodystrophy project, and COZY02, CombiGene's latest gene therapy project that targets severe chronic pain where there is currently a lack of good treatment options.
お知らせ • May 24CombiGene AB (publ) Approves Election of Marcus Isaksson as Board MemberCombiGene AB (publ) at its AGM held on May 23, 2024 approved election of Marcus Isaksson, as board member.
Reported Earnings • May 19First quarter 2024 earnings released: kr0.72 loss per share (vs kr0.74 loss in 1Q 2023)First quarter 2024 results: kr0.72 loss per share (improved from kr0.74 loss in 1Q 2023). Net loss: kr14.2m (loss narrowed 2.9% from 1Q 2023).
お知らせ • Mar 13CombiGene's Epilepsy Project CG01 Receives Patent in Two New CountriesCombiGene AB (publ) announced that the patent offices in Australia and India have granted patent for the epilepsy project CG01. The approval strengthens the project, which CombiGene recently has regained the global rights to.CG01 has previously been granted patents in the USA and Russia. CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.
お知らせ • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.
Reported Earnings • Feb 18Full year 2023 earnings released: kr1.80 loss per share (vs kr0.31 loss in FY 2022)Full year 2023 results: kr1.80 loss per share (further deteriorated from kr0.31 loss in FY 2022). Net loss: kr35.7m (loss widened 479% from FY 2022).
お知らせ • Dec 15+ 2 more updatesCombiGene AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025CombiGene AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Nov 12Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)Third quarter 2023 results: kr0.42 loss per share (down from kr0.20 profit in 3Q 2022). Revenue: kr1.17m (down 91% from 3Q 2022). Net loss: kr8.40m (down 313% from profit in 3Q 2022).
お知らせ • Oct 25+ 1 more updateCombiGene AB (publ), Annual General Meeting, May 23, 2024CombiGene AB (publ), Annual General Meeting, May 23, 2024.
New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.25m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (kr4.5m revenue, or US$409k). Market cap is less than US$10m (€9.25m market cap, or US$9.77m).
Board Change • Sep 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 27Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.23 profit in 2Q 2022)Second quarter 2023 results: kr0.32 loss per share (down from kr0.23 profit in 2Q 2022). Net loss: kr6.29m (down 239% from profit in 2Q 2022).
お知らせ • Jul 01CombiGene AB (publ) Announces Chief Executive Officer ChangesCombiGene AB (publ) announced that CEO Jan Nilsson will leave his position as CEO of the Company on September 1, 2023, when the Company's current COO Peter Ekolind will take over as CEO in accordance with current succession plan. Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industry. Many years of experience from a variety of positions have given Peter solid knowledge in product development, sales, marketing, preclinical development and GMP manufacturing. Peter has held several senior positions such as Business Area Manager, COO and CEO. He has served in a variety of firms, ranging from large multi-international companies to small development companies, with roles in business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiations, and research collaborations with universities. Peter has been Chief Operating Officer at CombiGene since September 2022. Jan Nilsson will continue to assist CombiGene on a consultancy basis, including the Company's involvement in the newly formed CCRM Nordic AB, where Jan was recently elected Chairman of the Board.
Reported Earnings • May 14First quarter 2023 earnings released: kr0.74 loss per share (vs kr0.14 loss in 1Q 2022)First quarter 2023 results: kr0.74 loss per share (further deteriorated from kr0.14 loss in 1Q 2022). Revenue: kr2.17m (down 85% from 1Q 2022). Net loss: kr14.6m (loss widened 445% from 1Q 2022).
Reported Earnings • Feb 18Full year 2022 earnings released: kr0.31 loss per share (vs kr1.21 profit in FY 2021)Full year 2022 results: kr0.31 loss per share (down from kr1.21 profit in FY 2021). Revenue: kr41.7m (down 54% from FY 2021). Net loss: kr6.16m (down 129% from profit in FY 2021).
お知らせ • Dec 03+ 3 more updatesCombiGene AB (publ), Annual General Meeting, May 25, 2023CombiGene AB (publ), Annual General Meeting, May 25, 2023.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.20 (up from kr0.62 loss in 3Q 2021). Revenue: kr13.5m (up kr13.1m from 3Q 2021). Net income: kr3.95m (up kr14.2m from 3Q 2021). Profit margin: 29% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.20 (up from kr0.62 loss in 3Q 2021). Revenue: kr13.5m (up kr13.1m from 3Q 2021). Net income: kr3.95m (up kr14.2m from 3Q 2021). Profit margin: 29% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue.
お知らせ • Sep 29CombiGene Appoints Peter Ekolind as COOCombiGene announced that Peter Ekolind joins the Company September 27, 2022, when he assumes the position of Chief Operating Officer, initially as a part-time assignment. Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industries. Many years of work in a variety of positions have given Peter a good knowledge of product development, sales, marketing preclinical development and GMP manufacturing. Peter has held several senior positions as, among other things, business area manager, COO and CEO. He has, in everything from large multi-international companies to small development companies, worked with business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiation and research collaborations with universities and colleges.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: kr0.23 (vs kr1.18 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.23 (up from kr1.18 loss in 2Q 2021). Revenue: kr14.6m (up kr13.8m from 2Q 2021). Net income: kr4.52m (up kr19.9m from 2Q 2021). Profit margin: 31% (up from net loss in 2Q 2021). The move to profitability was primarily driven by higher revenue.
Reported Earnings • May 13First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.95 loss in 1Q 2021)First quarter 2022 results: kr0.14 loss per share (up from kr0.95 loss in 1Q 2021). Revenue: kr14.5m (up 183% from 1Q 2021). Net loss: kr2.68m (loss narrowed 75% from 1Q 2021).
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 2 experienced directors. 1 highly experienced director. Independent Director Peter Nilsson is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 21CombiGene AB (publ), Annual General Meeting, May 19, 2022CombiGene AB (publ), Annual General Meeting, May 19, 2022, at 10:00 Central European Standard Time. Location: Freys Hotell, Bryggargatan 12 in Stockholm Stockholm Sweden Agenda: To consider Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group; to consider adoption of the profit and loss account and the balance sheet as well as of the consolidated profit and loss account and the consolidated balance sheet; to consider allocation of the company’s profit or loss according to the adopted balance sheet; to consider discharge from liability for the board members and the CEO; to consider Resolution on the number of board members, deputy board members, auditors and deputy auditors; to consider Resolution on the remuneration to the board of directors and auditors; to consider Resolution on instruction for the nomination committee; and to consider other matters.
お知らせ • Jan 18Combigene AB (Publ) Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human StudyCombiGene AB announced that the GMP production of CG01 has been made available for the concluding preclinical studies planned to enable First In Human study. This is the first large scale GMP production of CG01, and both the production itself and the subsequent testing were performed according to original plans. The data from the analyses will form a central part of future regulatory applications to support proceeding to clinical studies.